Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diamyd Medical has reported that its US Phase II clinical trial evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain has been published on the ClinicalTrials.gov website.
Subscribe to our email newsletter
The ClinicalTrials.gov website is a registry of federally and privately supported clinical trials conducted in the US and around the world.
The multi-centre, randomised, double-blind, placebo controlled Phase II clinical trial is designed to evaluate the safety and effect of NP2 Enkephalin with regard to pain relief, other pain medication usage and quality of life
The trial will enroll approximately 32 subjects with severe cancer pain.
The trial will have a four week double-blind main study period and an open label study extension, in which patients will be receive up to two additional doses of active NP2 Enkephalin.
The trial finalisation date has preliminary been fixed to one year from start date on ClinicalTrials.gov.
The drug candidate NP2 Enkephalin is designed to deliver the human Enkephalin gene, which naturally produces opioid peptides involved in pain control, directly to the site of pain in the nervous system.